Evidence map›Paper›PMID 36986886›Full record

ArticlePharmaceutics2023

Caveolin-Mediated Internalization of Fmoc-FF Nanogels in Breast Cancer Cell Lines.

Giovanni Smaldone, Elisabetta Rosa, Enrico Gallo, Carlo Diaferia, Giancarlo Morelli, Mariano Stornaiuolo, Antonella Accardo

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Giovanni SmaldoneIRCCS Synlab SDN, Via Gianturco 113, 80143 Naples, Italy.ORCID 0000-0002-1989-4740
Elisabetta RosaDepartment of Pharmacy and Research Centre on Bioactive Peptides (CIRPeB), University of Naples "Federico II", 80131 Naples, Italy.
Enrico GalloIRCCS Synlab SDN, Via Gianturco 113, 80143 Naples, Italy.ORCID 0000-0002-6132-4143
Carlo DiaferiaDepartment of Pharmacy and Research Centre on Bioactive Peptides (CIRPeB), University of Naples "Federico II", 80131 Naples, Italy.ORCID 0000-0002-9273-0136
Giancarlo MorelliDepartment of Pharmacy and Research Centre on Bioactive Peptides (CIRPeB), University of Naples "Federico II", 80131 Naples, Italy.
Mariano StornaiuoloDepartment of Pharmacy and Research Centre on Bioactive Peptides (CIRPeB), University of Naples "Federico II", 80131 Naples, Italy.ORCID 0000-0003-2200-5083
Antonella AccardoDepartment of Pharmacy and Research Centre on Bioactive Peptides (CIRPeB), University of Naples "Federico II", 80131 Naples, Italy.ORCID 0000-0002-7899-2359
University of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHydrogel nanoparticles, also known as nanogels (NGs), have been recently proposed as alternative supramolecular vehicles for the delivery of biologically relevant molecules like anticancer drugs and contrast agents. The inner compartment of peptide based NGs can be opportunely modified according to the chemical features of the cargo, thus improving its loading and release. A full understanding of the intracellular mechanism involved in nanogel uptake by cancer cells and tissues would further contribute to the potential diagnostic and clinical applications of these nanocarriers, allowing the fine tuning of their selectivity, potency, and activity. The structural characterization of nanogels were assessed by Dynamic Light Scattering (DLS) and Nanoparticles Tracking Analysis (NTA) analysis. Cells viability of Fmoc-FF nanogels was evaluated by MTT assay on six breast cancer cell lines at different incubation times (24, 48, and 72 h) and peptide concentrations (in the range 6.25 × 10

Indexed as

breast cancer cell linecaveolindiagnostic agentsendocytosisFmoc-FF peptidenanogel

Identifiers

PMID36986886
PMCPMC10051563
OpenAlexW4353067629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.